Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ardelyx, Inc. - Common Stock (NQ:ARDX)

4.045 +0.135 (+3.45%)
Streaming Delayed Price Updated: 12:45 PM EDT, Aug 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ardelyx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings
Presentation evaluates the long-term impact of XPHOZAH® on serum electrolytes and select nutrition biomarkers 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award
Award recognizes leading chronic kidney disease advocates 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C
Post hoc analysis supports a reduction of time to first bowel movement and a consistent improvement in abdominal symptoms, including pain, discomfort, and bloating, during 12 weeks of treatment 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Participate in Upcoming Investor Conferences
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions
First-of-its-kind partnership designed to educate and mobilize patients to imagine a healthier tomorrow 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Receives New Patent for Tenapanor
New patent covers IBSRELA® and XPHOZAH® and expires in 2042 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
Issued on behalf of Avant Technologies Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology’s 2025 Annual Meeting
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology’s Kidney Week
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Participate in Upcoming Investor Conferences
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces Changes to the Executive Leadership Team
From Ardelyx, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.